New stem cell combo aims to tame blood cancer with fewer side effects

NCT ID NCT07493538

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a stem cell transplant using a milder chemo and radiation regimen for people with blood cancers like AML and MDS. The goal is to see if this approach improves survival at 100 days after transplant. Participants receive donor stem cells along with drugs to prevent graft-versus-host disease. The study is currently recruiting 132 patients aged 2 to 75.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Treosulfan, Fludarabine, total body irradiation, tacrolimus, and cyclophosphamide
What this could lead to: If successful, this could offer a safer stem cell transplant option for people with blood cancers, reducing side effects and improving survival.
What could go wrong: This is a mid-stage trial with only 132 participants, so results may not apply to everyone. There are risks of infection, graft-versus-host disease, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA ACUTE MYELOID LEUKEMIA AML MDS MYELODYSPLASTIC SYNDROMES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Masonic Cancer Center at University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.